» Articles » PMID: 28158214

Communicating About Overdiagnosis: Learning from Community Focus Groups on Osteoporosis

Overview
Journal PLoS One
Date 2017 Feb 4
PMID 28158214
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Overdiagnosis is considered a risk associated with the diagnosis of osteoporosis-as many people diagnosed won't experience harm from the condition. As yet there's little evidence on community understanding of overdiagnosis outside cancer- where it is an established risk of some screening programs-or effective ways to communicate about it. We examined community understanding around overdiagnosis of osteoporosis, to optimise communication strategies about this problem.

Methods And Findings: Using a qualitative design we recruited a community sample of women, 50-80 years, from the Gold Coast community around Bond University, Australia, using random digit dialing, and conducted 5 focus groups with 41 women. A discussion guide and 4-part presentation were developed and piloted, with independent review from a consumer and clinical experts. Initial discussion had 4 segments: osteoporosis; bone density vs. other risk factors; medication; and overdiagnosis. The second half included the 4 short presentations and discussions on each. Analysis used Framework Analysis method. Initially participants described osteoporosis as bone degeneration causing some fear, demonstrated imprecise understanding of overdiagnosis, had a view osteoporosis couldn't be overdiagnosed as bone scans provided "clear cut" results, expressed belief in early diagnosis, and interest in prevention strategies enabling control. Following presentations, participants expressed some understanding of overdiagnosis, preference for describing osteoporosis as a "risk factor" not "disease", concern about a poor risk-benefit ratio for medications, and surprise and unease the definition of osteoporosis decided bone density of young women was "normal", without age adjustment. Limitations include English-speaking backgrounds of the sample and complex materials.

Conclusions: Our findings suggest a gap between community expectations and how experts sometimes arbitrarily set low diagnostic thresholds which label those at risk as "diseased". Optimal communication about overdiagnosis could build on community scepticism about treatments, encouraging weighing up benefits and harms of tests and diagnoses, and framing this information as positively adding to knowledge.

Citing Articles

Osteoporosis and risk of fracture: reference class problems are real.

Binney N Theor Med Bioeth. 2022; 43(5-6):375-400.

PMID: 36114828 PMC: 9700603. DOI: 10.1007/s11017-022-09590-3.


What is the effect of a decision aid on knowledge, values and preferences for lung cancer screening? An online pre-post study.

Clark S, Reuland D, Brenner A, Pignone M BMJ Open. 2021; 11(7):e045160.

PMID: 34244253 PMC: 8273450. DOI: 10.1136/bmjopen-2020-045160.


"I would not go to him": Focus groups exploring community responses to a public health campaign aimed at reducing unnecessary diagnostic imaging of low back pain.

Sharma S, Traeger A, Tcharkhedian E, Harrison J, Hersch J, Pickles K Health Expect. 2021; 24(2):648-658.

PMID: 33599389 PMC: 8077077. DOI: 10.1111/hex.13211.


How do patients and the public understand overtesting and overdiagnosis? A protocol for a thematic meta-synthesis of qualitative research.

Rozbroj T, Haas R, OConnor D, Thomas R, McCaffery K, Carter S BMJ Open. 2020; 10(7):e037283.

PMID: 32636285 PMC: 7342480. DOI: 10.1136/bmjopen-2020-037283.


Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare.

Moynihan R, Fabbri A, Parker L, Bero L BMJ Open. 2020; 10(5):e034195.

PMID: 32393611 PMC: 7223283. DOI: 10.1136/bmjopen-2019-034195.


References
1.
Reid I . Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiol. 2011; 40(9):1191-6. DOI: 10.1007/s00256-011-1164-9. View

2.
. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

3.
Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD001155. DOI: 10.1002/14651858.CD001155.pub2. View

4.
Moynihan R, Heath I, Henry D . Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002; 324(7342):886-91. PMC: 1122833. DOI: 10.1136/bmj.324.7342.886. View

5.
Waller J, Douglas E, Whitaker K, Wardle J . Women's responses to information about overdiagnosis in the UK breast cancer screening programme: a qualitative study. BMJ Open. 2013; 3(4). PMC: 3641428. DOI: 10.1136/bmjopen-2013-002703. View